The exponential growth of retinal disease globally, along with the increase in innovative therapeutics requiring frequent patient monitoring, have created pressure on healthcare systems to scan and process images for enhanced clinical information. Artificial intelligence (AI) models such as those developed by RetinAI can improve the speed, efficiency, and consistency with which image data is processed. RetinAI’s tools support diagnostic analyses and clinical workflows for monitoring of patient and treatment outcomes across several eye conditions such as Age-Related Macular Degeneration (including Geographic Atrophy), Diabetic Retinopathy, Diabetic Macular Edema, Glaucoma, and Retinal Vein Occlusion.
RetinAI will initially provide access to its CE-marked AI analysis models, to support the efficient processing of image data. As the portfolio of regulatory approved AI solutions expands, both companies expect additional features will also become available to Heidelberg Engineering customers. This technology is used today by healthcare and clinical research professionals to compute imaging biomarkers and track changes over time for some of the most common eye diseases.
